Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and γ-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 1, 2007, Pages 47-55

  Masunaga, Shin Ichiro ^a   Nagasawa, Hideko ^b   Nagata, Kenji ^a   Suzuki, Minoru ^a   Uto, Yoshihiro ^c   Hori, Hitoshi ^c   Kinashi, Yuko ^a   Ono, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Rays; Hypoxic fraction; Quiescent cell; Tirapazamine; Vascular disrupting agent

Indexed keywords

BROXURIDINE; CYTOTOXIN; N ACETYLCOLCHINOL PHOSPHATE; TIRAPAZAMINE; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GAMMA IRRADIATION; HYPOXIC CELL; IMMUNOFLUORESCENCE; MICRONUCLEUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GAMMA RAYS; MICE; ORGANOPHOSPHORUS COMPOUNDS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TIME FACTORS; TRIAZINES;

EID: 33751504322     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-006-0145-1     Document Type: Article

References (23)

1. Ando K, Koike S, Ohira C, Chen YJ, Nojima K, Ando S, Ohbuchi T, Kobayashi N, Shimizu W, Urano M (1999) Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int J Radiat Biol 75:505-512
2. Blakey DC, Westwood FR, Walker, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974-1983
3. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA (2002) ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253
4. Denekamp J (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181-196
5. Grosios K, Holwell SE, McGown AT, Petti GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318-1327
6. Horsman MR, Murata R (2003) Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57:1047-1055
7. Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M, Giaccia A (2001) Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21:1297-1310
8. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR (1988) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethyl-xanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78:439-445
9. Masunaga S, Ono K (2002) Significance of the response of quiescent cell populations within solid tumors in cancer therapy. J Radiat Res 43:11-25
10. Masunaga S, Ono K Hori H, Kinashi Y, Suzuki M, Takagaki M, Kasai S Nagasawa H, Uto Y (1999) Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells. Int J Hyperthermia 15:7-16
11. Micheletti G, Poli M, Borsotti DC, Martinelli M, Imberti B, Taraboletti G, Giavazzi R (2003) Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63:1534-1537
12. Moulder JE, Rockwell S (1984) Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10:695-712
13. Seng F, Ley K (1972) Simple synthesis of 3-amino-1,2,4-benzotriazine-1,4- dioxide. Angew Chem Int Ed Engl 11:1009-1010
14. Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M (1986) Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res 77:908-15
15. Siemann DW, Rojiani AM (2005) The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 62:846-853
16. Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491-2499
17. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FALM, Horsman MR, Marme D, LoRusso PM (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11:416-420
18. Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. (2006) Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res 66:2074-2080
19. Vaupel P (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14:198-206
20. Wilson WR, Li AE, Cowan DS, Siim BG (1998) Enhancement of tumor radiation response by the antivascular agent 5,6-dimethyl-xanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42:905-908
21. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242
22. Zhao D, Jiang L, Hahn EW, Mason RP (2005a) Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 62:872-880
23. Zhao L, Ching L-M, Kestell P, Kelland LR, Baguley BC (2005b) Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenine-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 116:322-326